Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134964 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Safety and PK Study of OLT1177 Capsules
A Phase 1 study, sponsored by Olatec Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02134964: Completed Phase 1 study, sponsored by Olatec Therapeutics.
NCT02134964 is a Phase 1 study that has completed, run by Olatec Therapeutics. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02134964, a Phase 1 study, has completed, sponsored by Olatec Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers after administration of single or multiple dose(s) of investigational drug (OLT1177 Caps or Placebo Caps). A total of 36 subjects will be enrolled across 6 cohorts, and subjects in each cohort will be randomized in a ratio of 5 active to 1 placebo.
Primary Outcome
Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the event.
Interventions
- DRUG Placebo Capsules
- DRUG OLT1177 Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
What the finished NCT02134964 record still lists
NCT02134964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Capsules is the first listed.
NCT02134964 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02134964 about?
NCT02134964 is a clinical study titled "Phase 1 Safety and PK Study of OLT1177 Capsules". This study is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers after administration of single or multiple dose(s) of investigational drug (OLT1177 Caps or Placebo Caps). A total of 36 subjects will be enrolled across 6 cohorts, and subjects in each cohort will ...
What is the current status of trial NCT02134964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2014-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02134964?
The interventions under investigation include: Placebo Capsules (DRUG), OLT1177 Capsules (DRUG).
Who is sponsoring clinical trial NCT02134964?
This trial is sponsored by Olatec Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02134964's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia